151 lines
60 KiB
Text
151 lines
60 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK612354">
|
|
<meta name="ncbi_domain" content="nciprotocols">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK612354/?report=reader">
|
|
<meta name="ncbi_pagename" content="Leukocyte Proliferation Assay (Immunostimulation and Immunosuppression) - National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Leukocyte Proliferation Assay (Immunostimulation and Immunosuppression) - National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/nciprotocols/ncipr57/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/nciprotocols/ncipr41/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/nciprotocols/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols [Internet]">
|
|
<meta name="citation_title" content="Leukocyte Proliferation Assay (Immunostimulation and Immunosuppression)">
|
|
<meta name="citation_publisher" content="National Cancer Institute (US)">
|
|
<meta name="citation_date" content="2024/07">
|
|
<meta name="citation_author" content="Timothy M. Potter">
|
|
<meta name="citation_author" content="Edward Cedrone">
|
|
<meta name="citation_author" content="Sarah L. Skoczen">
|
|
<meta name="citation_author" content="Barry W. Neun">
|
|
<meta name="citation_author" content="Marina A. Dobrovolskaia">
|
|
<meta name="citation_pmid" content="39999260">
|
|
<meta name="citation_doi" content="10.17917/PJNB-JJ95">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK612354/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Leukocyte Proliferation Assay (Immunostimulation and Immunosuppression)">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Cancer Institute (US)">
|
|
<meta name="DC.Contributor" content="Timothy M. Potter">
|
|
<meta name="DC.Contributor" content="Edward Cedrone">
|
|
<meta name="DC.Contributor" content="Sarah L. Skoczen">
|
|
<meta name="DC.Contributor" content="Barry W. Neun">
|
|
<meta name="DC.Contributor" content="Marina A. Dobrovolskaia">
|
|
<meta name="DC.Date" content="2024/07">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK612354/">
|
|
<meta name="description" content="This document describes a protocol for assessing the effect of a nanoparticle formulation on the basic immunologic function of human lymphocytes, i.e. measurement of lymphocyte proliferative responses [1, 2]. This assay will allow for measurement of a nanoparticles’ ability to induce proliferative response of human lymphocytes (part A) or to suppress that induced by phytohemaglutinin (PHA-M) (part B). Parts A and B can typically be run concurrently on the same test plate. Part A is also available as a separate protocol entitled ITA-6.2. Part B is available as a separate protocol with a modification to allow for 24 hr exposure to nanoparticle prior to challenge with PHA-M, and is entitled ITA-6.3.">
|
|
<meta name="og:title" content="Leukocyte Proliferation Assay (Immunostimulation and Immunosuppression)">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="This document describes a protocol for assessing the effect of a nanoparticle formulation on the basic immunologic function of human lymphocytes, i.e. measurement of lymphocyte proliferative responses [1, 2]. This assay will allow for measurement of a nanoparticles’ ability to induce proliferative response of human lymphocytes (part A) or to suppress that induced by phytohemaglutinin (PHA-M) (part B). Parts A and B can typically be run concurrently on the same test plate. Part A is also available as a separate protocol entitled ITA-6.2. Part B is available as a separate protocol with a modification to allow for 24 hr exposure to nanoparticle prior to challenge with PHA-M, and is entitled ITA-6.3.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK612354/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-nciprotocols-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/nciprotocols/ncipr43/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK612354/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8C0F8D7C8E7C41000000000082006D.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK612354/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/nciprotocols/ncipr57/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">NCL Method ITA-6.1, Leukocyte Proliferation Assay (Immunostimulation and Immunosuppression): Version 4.2</div><div class="j">National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols [Internet]</div></div><div class="tail"><a href="/books/n/nciprotocols/ncipr41/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK612354/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK612354/&text=Leukocyte%20Proliferation%20Assay%20(Immunostimulation%20and%20Immunosuppression)"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/nciprotocols/?report=reader">Title Information</a><a href="/books/n/nciprotocols/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK612354/?report=classic">Switch to classic view</a><a href="/books/NBK612354/pdf/Bookshelf_NBK612354.pdf">PDF (447K)</a><a href="/books/NBK612354/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK612354%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8C0F8D7C8E7C41000000000082006D.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK612354_"><span class="label">NCL Method ITA-6.1</span><span class="title" itemprop="name">Leukocyte Proliferation Assay (Immunostimulation and Immunosuppression)</span></h1><div class="subtitle whole_rhythm">Version 4.2</div><p class="contribs">Potter TM, Cedrone E, Skoczen SL, et al.</p><p class="fm-aai"><a href="#_NBK612354_pubdet_">Publication Details</a></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="ncipr43.s1"><h2 id="_ncipr43_s1_">1. Introduction</h2><p>This document describes a protocol for assessing the effect of a nanoparticle formulation on the basic immunologic function of human lymphocytes, i.e. measurement of lymphocyte proliferative responses [<a class="bibr" href="#ncipr43.ref1" rid="ncipr43.ref1">1</a>, <a class="bibr" href="#ncipr43.ref2" rid="ncipr43.ref2">2</a>]. This assay will allow for measurement of a nanoparticles’ ability to induce proliferative response of human lymphocytes (part A) or to suppress that induced by phytohemaglutinin (PHA-M) (part B). Parts A and B can typically be run concurrently on the same test plate. Part A is also available as a separate protocol entitled ITA-6.2. Part B is available as a separate protocol with a modification to allow for 24 hr exposure to nanoparticle prior to challenge with PHA-M, and is entitled ITA-6.3.</p></div><div id="ncipr43.s2"><h2 id="_ncipr43_s2_">2. Principles</h2><p>Lymphocytes are isolated from human blood anti-coagulated with Li-heparin using Ficoll-Paque Premium solution. The isolated cells are incubated with or without phytohemaglutinin (PHA-M) in the presence or absence of nanoparticles and analyzed spectrophotometrically via the MTT (3-(4, 5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) assay.</p></div><div id="ncipr43.s3"><h2 id="_ncipr43_s3_">3. Reagents, Materials, and Equipment</h2><blockquote><p><i>Note: The NCL does not endorse any of the suppliers listed below; these reagents were used in the development of the protocol and their inclusion is for informational purposes only. Equivalent supplies from alternate vendors can be substituted. Please note that suppliers may undergo a name change due to a variety of factors. Brands and part numbers typically remain consistent but may also change over time</i>.</p></blockquote><dl id="ncipr43.l1" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>3.1.</dt><dd id="ncipr43.lt1"><p class="no_top_margin">Reagents
|
|
<dl id="ncipr43.l2" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>3.1.1.</dt><dd id="ncipr43.lt2"><p class="no_top_margin">Human blood anti-coagulated with Li-heparin and obtained from at least 3 healthy donors</p></dd></dl><dl class="bkr_refwrap"><dt>3.1.2.</dt><dd id="ncipr43.lt3"><p class="no_top_margin">Ficoll-Paque Premium (GE Life Sciences, 17-5442-02)</p></dd></dl><dl class="bkr_refwrap"><dt>3.1.3.</dt><dd id="ncipr43.lt4"><p class="no_top_margin">Phosphate Buffered Saline (PBS) (GE Life Sciences, Hyclone SH30256.01)</p></dd></dl><dl class="bkr_refwrap"><dt>3.1.4.</dt><dd id="ncipr43.lt5"><p class="no_top_margin">Phytohemaglutinin (PHA-M) (Sigma, L8902)</p></dd></dl><dl class="bkr_refwrap"><dt>3.1.5.</dt><dd id="ncipr43.lt6"><p class="no_top_margin">Fetal Bovine Serum (FBS) (GE Life Sciences, Hyclone, SH30070.03)</p></dd></dl><dl class="bkr_refwrap"><dt>3.1.6.</dt><dd id="ncipr43.lt7"><p class="no_top_margin">RPMI-1640 (GE Life Sciences, HyClone, SH30096.01)</p></dd></dl><dl class="bkr_refwrap"><dt>3.1.7.</dt><dd id="ncipr43.lt8"><p class="no_top_margin">Hank’s balanced salt solution (HBSS) (Gibco, 14175-095)</p></dd></dl><dl class="bkr_refwrap"><dt>3.1.8.</dt><dd id="ncipr43.lt9"><p class="no_top_margin">Penicillin streptomycin solution (GE Life Sciences, Hyclone, SV30010)</p></dd></dl><dl class="bkr_refwrap"><dt>3.1.9.</dt><dd id="ncipr43.lt10"><p class="no_top_margin">Trypan Blue solution (Invitrogen, 15250-061)</p></dd></dl><dl class="bkr_refwrap"><dt>3.1.10.</dt><dd id="ncipr43.lt11"><p class="no_top_margin">MTT (3-(4, 5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) (Sigma, M5655)</p></dd></dl><dl class="bkr_refwrap"><dt>3.1.11.</dt><dd id="ncipr43.lt12"><p class="no_top_margin">L-glutamine (GE Life Sciences, Hyclone, SH30034.01)</p></dd></dl><dl class="bkr_refwrap"><dt>3.1.12.</dt><dd id="ncipr43.lt13"><p class="no_top_margin">Glycine (Sigma, G7403)</p></dd></dl><dl class="bkr_refwrap"><dt>3.1.13.</dt><dd id="ncipr43.lt14"><p class="no_top_margin">Sodium chloride (Sigma, S7653)</p></dd></dl></dl></p></dd></dl><dl class="bkr_refwrap"><dt>3.2.</dt><dd id="ncipr43.lt15"><p class="no_top_margin">Materials
|
|
<dl id="ncipr43.l3" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>3.2.1.</dt><dd id="ncipr43.lt16"><p class="no_top_margin">Pipettes covering a range of 0.05 to 10 mL</p></dd></dl><dl class="bkr_refwrap"><dt>3.2.2.</dt><dd id="ncipr43.lt17"><p class="no_top_margin">96-well round bottom plates</p></dd></dl><dl class="bkr_refwrap"><dt>3.2.3.</dt><dd id="ncipr43.lt18"><p class="no_top_margin">96-well flat bottom plates</p></dd></dl><dl class="bkr_refwrap"><dt>3.2.4.</dt><dd id="ncipr43.lt19"><p class="no_top_margin">Polypropylene tubes, 50 and 15 mL</p></dd></dl></dl></p></dd></dl><dl class="bkr_refwrap"><dt>3.3.</dt><dd id="ncipr43.lt20"><p class="no_top_margin">Equipment
|
|
<dl id="ncipr43.l4" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>3.3.1.</dt><dd id="ncipr43.lt21"><p class="no_top_margin">Centrifuge</p></dd></dl><dl class="bkr_refwrap"><dt>3.3.2.</dt><dd id="ncipr43.lt22"><p class="no_top_margin">Refrigerator, 2-8ºC</p></dd></dl><dl class="bkr_refwrap"><dt>3.3.3.</dt><dd id="ncipr43.lt23"><p class="no_top_margin">Freezer, −20ºC</p></dd></dl><dl class="bkr_refwrap"><dt>3.3.4.</dt><dd id="ncipr43.lt24"><p class="no_top_margin">Cell culture incubator with 5% CO<sub>2</sub> and 95% humidity</p></dd></dl><dl class="bkr_refwrap"><dt>3.3.5.</dt><dd id="ncipr43.lt25"><p class="no_top_margin">Biohazard safety cabinet approved for level II handling of biological material</p></dd></dl><dl class="bkr_refwrap"><dt>3.3.6.</dt><dd id="ncipr43.lt26"><p class="no_top_margin">Inverted microscope</p></dd></dl><dl class="bkr_refwrap"><dt>3.3.7.</dt><dd id="ncipr43.lt27"><p class="no_top_margin">Vortex</p></dd></dl><dl class="bkr_refwrap"><dt>3.3.8.</dt><dd id="ncipr43.lt28"><p class="no_top_margin">Hemocytometer</p></dd></dl><dl class="bkr_refwrap"><dt>3.3.9.</dt><dd id="ncipr43.lt29"><p class="no_top_margin">Plate reader capable of operating at 570 nm</p></dd></dl></dl></p></dd></dl></dl></div><div id="ncipr43.s4"><h2 id="_ncipr43_s4_">4. Reagent and Control Preparation</h2><dl id="ncipr43.l5" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>4.1.</dt><dd id="ncipr43.lt30"><p class="no_top_margin">
|
|
<u>Complete RPMI-1640 Medium</u>
|
|
</p><p>The complete RPMI medium should contain the following reagents:</p><p>10% FBS (heat inactivated)</p><p>2 mM L-glutamine</p><p>100 U/mL penicillin</p><p>100 µg/mL streptomycin sulfate</p><p>Store at 2-8ºC, protected from light for no longer than 1 month. Before use, warm in a water bath.</p></dd></dl><dl class="bkr_refwrap"><dt>4.2.</dt><dd id="ncipr43.lt31"><p class="no_top_margin">
|
|
<u>Phytohemaglutinin-M Stock Solution, 1 mg/mL (PHA-M Stock)</u>
|
|
</p><p>Add 1 mL of sterile PBS or cell culture medium per 1 mg of PHA-M to the vial and gently rotate to mix. Store daily use aliquots at a nominal temperature of −20ºC. Avoid repeated freezing/thawing.</p></dd></dl><dl class="bkr_refwrap"><dt>4.3.</dt><dd id="ncipr43.lt32"><p class="no_top_margin">
|
|
<u>Positive Control</u>
|
|
</p><p>Dilute PHA-M stock in cell culture medium to a final concentration of 100 µg/mL and prepare working solutions at the following concentrations: PC1 - 20 µg/mL, PC2 - 10 µg/mL and PC3 - 5 µg/mL. Final concentrations of PC1, PC2 and PC3 in the well after addition of cell suspension will be 10, 5 and 2.5 µg/mL, respectively.
|
|
<blockquote><p><i>Note: The volume of PC1 needed for the assay depends on the number of samples, as this control will be used to prepare samples combining nanoparticle treatment with PC. When comparing leukocyte proliferation in nanoparticle+PC sample use proliferation in PC2 as benchmark</i>.</p></blockquote></p></dd></dl><dl class="bkr_refwrap"><dt>4.4.</dt><dd id="ncipr43.lt33"><p class="no_top_margin">
|
|
<u>Negative Control</u>
|
|
</p><p>Use PBS as a negative control. Process this control in the same way as the test samples.</p></dd></dl><dl class="bkr_refwrap"><dt>4.5.</dt><dd id="ncipr43.lt34"><p class="no_top_margin">
|
|
<u>Vehicle Control</u>
|
|
</p><p>Vehicle control is the buffer or media used to formulate test nanomaterials. Common excipients used in nanoformulations are trehalose, sucrose, and albumin. However, other reagents and materials are also used alone or in combination. Vehicle control should match formulation buffer of the test-nanomaterial by both composition and concentration. This control can be skipped if nanoparticles are stored in PBS.</p></dd></dl><dl class="bkr_refwrap"><dt>4.6.</dt><dd id="ncipr43.lt35"><p class="no_top_margin">
|
|
<u>Heat-Inactivated Fetal Bovine Serum</u>
|
|
</p><p>Thaw a bottle of FBS at room temperature, or overnight at 2-8ºC and allow to equilibrate to room temperature. Incubate 30 minutes at 56ºC in a water bath, mixing every 5 minutes. Single use aliquots may be stored at 2-8ºC for up to one month or at a nominal temperature of −20ºC indefinitely.</p></dd></dl><dl class="bkr_refwrap"><dt>4.7.</dt><dd id="ncipr43.lt36"><p class="no_top_margin">
|
|
<u>MTT Solution</u>
|
|
</p><p>Prepare MTT solution in PBS at a final concentration of 5 mg/mL. Store for up to one month at 4ºC in dark (e.g. wrap the storage bottle in foil).</p></dd></dl><dl class="bkr_refwrap"><dt>4.8.</dt><dd id="ncipr43.lt37"><p class="no_top_margin">
|
|
<u>Glycine Buffer</u>
|
|
</p><p>Prepare buffer by dissolving glycine and NaCl in water to a final concentration of 0.1 M for glycine (MW 75.07 g/mol) and 0.1 M for NaCl (MW 58.44 g/mol). Adjust pH to 10.5. Store at room temperature.</p></dd></dl><dl class="bkr_refwrap"><dt>4.9.</dt><dd id="ncipr43.lt38"><p class="no_top_margin">
|
|
<u>Research Donor Blood</u>
|
|
</p><p>The blood from at least three donor volunteers should be drawn in vacutainers containing Li-heparin as anti-coagulant. The first 10 cc collected during phlebotomy should be discarded. Cells from each donor should be tested separately.</p></dd></dl></dl></div><div id="ncipr43.s5"><h2 id="_ncipr43_s5_">5. Preparation of Study Samples</h2><p>This assay requires 3.0 mL of nanoparticles dissolved/resuspended in complete culture medium to a concentration 4X the highest tested concentration. The concentration is selected based on the plasma concentration of the nanoparticle at the intended therapeutic dose. For the purpose of this protocol this concentration is called the “theoretical plasma concentration”. Considerations for estimating theoretical plasma concentration were reviewed elsewhere [<a class="bibr" href="#ncipr43.ref3" rid="ncipr43.ref3">3</a>] and are summarized in <a href="/books/NBK612354/box/ncipr43.box1/?report=objectonly" target="object" rid-ob="figobncipr43box1">Box 1</a> below.</p><div id="ncipr43.box1" class="box boxed-text-box whole_rhythm hide-overflow"><h3><span class="label">Box 1</span><span class="title">Example Calculation to Determine Nanoparticle Concentration for In Vitro Tests</span></h3><p>In this example, we assume a mouse dose of 123 mg/kg. Therefore, the scaled equivalent human dose would be:
|
|
<div class="pmc_disp_formula whole_rhythm clearfix" id="ncipr43.deq1"><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow twelve_col"><math id="ncipr43.eq1" display="block"><mrow><mi>H</mi><mi>u</mi><mi>m</mi><mi>a</mi><mi>n</mi><mtext> </mtext><mi>d</mi><mi>o</mi><mi>s</mi><mi>e</mi><mo>=</mo><mfrac><mrow><mi>m</mi><mi>o</mi><mi>u</mi><mi>s</mi><mi>e</mi><mtext> </mtext><mi>d</mi><mi>o</mi><mi>s</mi><mi>e</mi></mrow><mrow><mn>12.3</mn></mrow></mfrac><mo>=</mo><mfrac><mrow><mn>123</mn><mtext> </mtext><mi>m</mi><mi>g</mi><mo>/</mo><mi>k</mi><mi>g</mi></mrow><mrow><mn>12.3</mn></mrow></mfrac><mo>=</mo><mn>10</mn><mtext> </mtext><mi>m</mi><mi>g</mi><mo>/</mo><mi>k</mi><mi>g</mi></mrow></math></div><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow last bk_equ_label "><div><span class="nowrap"></span></div></div></div></p><p>Blood volume constitutes approximately 8% of the body weight. Therefore, an average human of 70 kg body weight has approximately 5.6 L of blood. Assuming all the nanoparticle injected goes into the systemic circulation, this provides a rough approximation of the potential maximum nanoparticle concentration in blood, which is used as the in vitro test concentration.</p><div class="pmc_disp_formula whole_rhythm clearfix" id="ncipr43.deq2"><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow twelve_col">
|
|
<math id="ncipr43.eq2" display="block"><mrow><mi>i</mi><mi>n</mi><mtext> </mtext><mi>v</mi><mi>i</mi><mi>t</mi><mi>r</mi><mi>o</mi><mtext> </mtext><mi>c</mi><mi>o</mi><mi>n</mi><mi>c</mi><mi>e</mi><mi>n</mi><mi>t</mi><mi>r</mi><mi>a</mi><mi>t</mi><mi>i</mi><mi>o</mi><msub><mi>n</mi><mrow><mi>h</mi><mi>u</mi><mi>m</mi><mi>a</mi><mi>n</mi><mtext> </mtext><mi>m</mi><mi>a</mi><mi>t</mi><mi>r</mi><mi>i</mi><mi>x</mi></mrow></msub><mo>=</mo><mfrac><mrow><mi>h</mi><mi>u</mi><mi>m</mi><mi>a</mi><mi>n</mi><mtext> </mtext><mi>d</mi><mi>o</mi><mi>s</mi><mi>e</mi></mrow><mrow><mi>h</mi><mi>u</mi><mi>m</mi><mi>a</mi><mi>n</mi><mtext> </mtext><mi>b</mi><mi>l</mi><mi>o</mi><mi>o</mi><mi>d</mi><mtext> </mtext><mi>v</mi><mi>o</mi><mi>l</mi><mi>u</mi><mi>m</mi><mi>e</mi></mrow></mfrac><mo>=</mo><mfrac><mrow><mn>70</mn><mtext> </mtext><mi>k</mi><mi>g</mi><mo>∗</mo><mn>10</mn><mtext> </mtext><mi>m</mi><mi>g</mi><mo>/</mo><mi>k</mi><mi>g</mi></mrow><mrow><mn>5.6</mn><mtext> </mtext><mi>L</mi></mrow></mfrac><mo>=</mo><mn>0.125</mn><mtext> </mtext><mi>m</mi><mi>g</mi><mo>/</mo><mi>m</mi><mi>L</mi></mrow></math>
|
|
</div><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow last bk_equ_label "><div><span class="nowrap"></span></div></div></div></div><p>The assay will evaluate 4 concentrations: 10X (or when feasible 100X, 30X or 5X) of theoretical plasma concentration, theoretical plasma concentration, and two 1:5 serial dilutions of the theoretical plasma concentration. When the intended therapeutic concentration is unknown, the highest final concentration is 1 mg/mL or the highest reasonably achievable concentration.</p><p>For example, if the final theoretical plasma concentration to be tested is 0.2 mg/mL, then a stock of 8 mg/mL will be prepared and diluted 2-fold (4 mg/mL). For the purpose of this document, these stocks are referred to as stock A (4 mg/mL or 2X of the highest tested concentration) and stock B (8 mg/mL or 4X of the highest tested concentration). Both stocks will then be diluted 10-fold (0.4 mg/mL and 0.8 mg/mL for stock A and stock B, respectively), followed by two 1:5 serial dilutions (stock A - 0.08 and 0.016 mg/mL, and stock B - 0.16 and 0.032 mg/mL). Stock A and its dilutions (group A) are used for the nanoparticle only treatments (part A). Stock B and its dilutions (group B) are used for the preparation of the nanoparticle + PC treatments (part B). When 0.1 mL of each sample from group A is mixed with 0.1 mL of cell suspension the final nanoparticle concentrations in these samples will also be 2.0, 0.2, 0.04 and 0.008 mg/mL. When 0.05 mL of each sample from group B is added to the plate and mixed with 0.05 mL of positive control 1 (PC 1) and 0.1 mL of cell suspension, the final nanoparticle concentrations tested in the assay are: 2.0, 0.2, 0.04 and 0.008 mg/mL.</p></div><div id="ncipr43.s6"><h2 id="_ncipr43_s6_">6. Isolation of Human Lymphocytes</h2><dl id="ncipr43.l6" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>6.1.</dt><dd id="ncipr43.lt39"><p class="no_top_margin">Place freshly drawn blood into 15 or 50 mL conical centrifuge tubes, add an equal volume of room-temperature PBS, and mix well.</p></dd></dl><dl class="bkr_refwrap"><dt>6.2.</dt><dd id="ncipr43.lt40"><p class="no_top_margin">Slowly layer the Ficoll-Paque solution underneath the blood/PBS mixture by placing the tip of the pipet containing Ficoll-Paque at the bottom of the blood sample tube. Alternatively, the blood/PBS mixture may be slowly layered over the Ficoll-Paque solution. Use 3 mL of Ficoll-Paque solution per 4 mL of blood/PBS mixture. For example, when using a 50 mL conical tube, overlay 20 mL of diluted blood over 15 mL of Ficoll-Paque solution.
|
|
<blockquote><p><i>Note: To maintain Ficoll-blood interface it is helpful to hold the tube at a 45º angle</i>.</p></blockquote></p></dd></dl><dl class="bkr_refwrap"><dt>6.3.</dt><dd id="ncipr43.lt41"><p class="no_top_margin">Centrifuge 30 min at 900xg, 18-20ºC, without brake.
|
|
<blockquote><p><i>Note: For certain types of centrifuges it may be advisable to set acceleration speed to minimum as well</i>.</p></blockquote></p></dd></dl><dl class="bkr_refwrap"><dt>6.4.</dt><dd id="ncipr43.lt42"><p class="no_top_margin">Using a sterile pipet, remove the upper layer containing plasma and platelets and discard it.</p></dd></dl><dl class="bkr_refwrap"><dt>6.5.</dt><dd id="ncipr43.lt43"><p class="no_top_margin">Using a fresh sterile pipet, transfer the mononuclear cell layer into another centrifuge tube.</p></dd></dl><dl class="bkr_refwrap"><dt>6.6.</dt><dd id="ncipr43.lt44"><p class="no_top_margin">Wash cells by adding an excess of HBSS and centrifuging for 10 min at 400xg, 18-20ºC. The HBSS volume should be ~3 times the volume of mononuclear layer.
|
|
<blockquote><p><i>Note: Usually 4 mL of blood/PBS mixture results in ~ 2 mL of mononuclear layer and requires at least 6 mL of HBSS for the wash step. We use 10 mL of HBSS per each 2 mL of cells</i>.</p></blockquote></p></dd></dl><dl class="bkr_refwrap"><dt>6.7.</dt><dd id="ncipr43.lt45"><p class="no_top_margin">Discard supernatant and repeat wash step one more time.</p></dd></dl><dl class="bkr_refwrap"><dt>6.8.</dt><dd id="ncipr43.lt46"><p class="no_top_margin">Resuspend cells in complete RPMI-1640 medium. Dilute cells 1:5 or 1:10 with trypan blue, count cells and determine viability using trypan blue exclusion. If viability is at least 90%, proceed to the next step.</p></dd></dl></dl></div><div id="ncipr43.s7"><h2 id="_ncipr43_s7_">7. Experimental Procedure</h2><dl id="ncipr43.l7" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>7.1.</dt><dd id="ncipr43.lt47"><p class="no_top_margin">Adjust cell concentration to 1 × 10<sup>6</sup> cells/mL using complete RPMI medium.</p></dd></dl><dl class="bkr_refwrap"><dt>7.2.</dt><dd id="ncipr43.lt48"><p class="no_top_margin">Dispense a) 100 µL of controls; b) 100 µL test samples from group A (i.e. at 2X the final test concentration) for nanoparticle treatment only; and c) 50 µL of test samples from group B (i.e. at 4X the final test concentration) for nanoparticle plus positive control treatment and 50 µL of PC1 per well on a 96-well <u>round</u> bottom plate. Each dilution is analyzed three times in duplicate. Always include cell-free controls as well (i.e., 100 µL nanoparticles (at 2X final test concentration concentration) and 100 µL of cell culture media). See <a href="#ncipr43.app1">Appendix</a> for example plate map.</p></dd></dl><dl class="bkr_refwrap"><dt>7.3.</dt><dd id="ncipr43.lt49"><p class="no_top_margin">Dispense 100 µL of cell suspension (or cell culture medium for cell-free controls) per well. Gently shake the plate to allow all components to mix. Repeat <a href="#ncipr43.lt47">steps 7.1</a>–<a href="#ncipr43.lt49">7.3</a> for each individual donor.</p></dd></dl><dl class="bkr_refwrap"><dt>7.4.</dt><dd id="ncipr43.lt50"><p class="no_top_margin">Incubate 72±2 hours in a humidified 37ºC, 5% CO<sub>2</sub> incubator.</p></dd></dl><dl class="bkr_refwrap"><dt>7.5.</dt><dd id="ncipr43.lt51"><p class="no_top_margin">Centrifuge plate for 5 minutes at 700xg. Aspirate medium, leaving cells and approximately 50 µL of medium behind. Add 150 µL of fresh medium to each well.</p></dd></dl><dl class="bkr_refwrap"><dt>7.6.</dt><dd id="ncipr43.lt52"><p class="no_top_margin">Add 50 µL of MTT to all wells.</p></dd></dl><dl class="bkr_refwrap"><dt>7.7.</dt><dd id="ncipr43.lt53"><p class="no_top_margin">Cover in aluminum foil and incubate in a humidified 37ºC, 5% CO<sub>2</sub> incubator for 4 hours.</p></dd></dl><dl class="bkr_refwrap"><dt>7.8.</dt><dd id="ncipr43.lt54"><p class="no_top_margin">Remove plate from incubator and spin at 700xg for 5 minutes.</p></dd></dl><dl class="bkr_refwrap"><dt>7.9.</dt><dd id="ncipr43.lt55"><p class="no_top_margin">Aspirate media and MTT.</p></dd></dl><dl class="bkr_refwrap"><dt>7.10.</dt><dd id="ncipr43.lt56"><p class="no_top_margin">Add 200 µL of DMSO to all wells.</p></dd></dl><dl class="bkr_refwrap"><dt>7.11.</dt><dd id="ncipr43.lt57"><p class="no_top_margin">Add 25 µL of glycine buffer to all wells.
|
|
<blockquote><p><i>Note: You may need to pipet the content of the plate up and down several times to ensure that all formazan crystals are solubilized</i>.</p></blockquote></p></dd></dl><dl class="bkr_refwrap"><dt>7.12.</dt><dd id="ncipr43.lt58"><p class="no_top_margin">Transfer 200 µL of the plate into a 96-well <u>flat</u> bottom plate
|
|
<blockquote><p><i>Note: The transfer into flat bottom plate may be skipped if plate reader can operate with round bottom plates</i>.</p></blockquote></p></dd></dl><dl class="bkr_refwrap"><dt>7.12.</dt><dd id="ncipr43.lt59"><p class="no_top_margin">Read at 570 nm on plate reader.</p></dd></dl></dl></div><div id="ncipr43.s8"><h2 id="_ncipr43_s8_">8. Calculations</h2><dl id="ncipr43.l8" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>8.1.</dt><dd id="ncipr43.lt60"><p class="no_top_margin">A Percent Coefficient of Variation should be calculated for each control or test according to the following formula:
|
|
<div class="pmc_disp_formula whole_rhythm clearfix" id="ncipr43.deq3"><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow twelve_col"><math id="ncipr43.eq3" display="block"><mrow><mi>%</mi><mi>C</mi><mi>V</mi><mo>=</mo><mfrac><mrow><mtext mathvariant="italic">standard deviation</mtext></mrow><mrow><mi>m</mi><mi>e</mi><mi>a</mi><mi>n</mi></mrow></mfrac><mo>∗</mo><mn>100</mn><mi>%</mi></mrow></math></div><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow last bk_equ_label "><div><span class="nowrap"></span></div></div></div></p></dd></dl><dl class="bkr_refwrap"><dt>8.2.</dt><dd id="ncipr43.lt61"><p class="no_top_margin">Analyze the data as follows:
|
|
<div class="pmc_disp_formula whole_rhythm clearfix" id="ncipr43.deq4"><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow twelve_col"><math id="ncipr43.eq4" display="block"><mrow><mi>%</mi><mtext> </mtext><mi>P</mi><mi>r</mi><mi>o</mi><mi>l</mi><mi>i</mi><mi>f</mi><mi>e</mi><mi>r</mi><mi>a</mi><mi>t</mi><mi>i</mi><mi>o</mi><mi>n</mi><mo>=</mo><mfrac><mrow><mrow><mo>(</mo><mrow><mi>M</mi><mi>e</mi><mi>a</mi><mi>n</mi><mtext> </mtext><mi>O</mi><msub><mi>D</mi><mrow><mi>T</mi><mi>e</mi><mi>s</mi><mi>t</mi><mtext> </mtext><mi>s</mi><mi>a</mi><mi>m</mi><mi>p</mi><mi>l</mi><mi>e</mi></mrow></msub><mo>−</mo><mi>M</mi><mi>e</mi><mi>a</mi><mi>n</mi><mtext> </mtext><mi>O</mi><msub><mi>D</mi><mrow><mi>U</mi><mi>n</mi><mi>t</mi><mi>r</mi><mi>e</mi><mi>a</mi><mi>t</mi><mi>e</mi><mi>d</mi><mtext> </mtext><mi>c</mi><mi>e</mi><mi>l</mi><mi>l</mi><mi>s</mi></mrow></msub></mrow><mo>)</mo></mrow></mrow><mrow><mi>M</mi><mi>e</mi><mi>a</mi><mi>n</mi><mtext> </mtext><mi>O</mi><msub><mi>D</mi><mrow><mi>U</mi><mi>n</mi><mi>t</mi><mi>r</mi><mi>e</mi><mi>a</mi><mi>t</mi><mi>e</mi><mi>d</mi><mtext> </mtext><mi>c</mi><mi>e</mi><mi>l</mi><mi>l</mi><mi>s</mi></mrow></msub></mrow></mfrac><mo>∗</mo><mn>100</mn><mi>%</mi></mrow></math></div><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow last bk_equ_label "><div><span class="nowrap"></span></div></div></div>
|
|
<div class="pmc_disp_formula whole_rhythm clearfix" id="ncipr43.deq5"><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow twelve_col"><math id="ncipr43.eq5" display="block"><mrow><mi>%</mi><mtext> </mtext><mi>P</mi><mi>r</mi><mi>o</mi><mi>l</mi><mi>i</mi><mi>f</mi><mi>e</mi><mi>r</mi><mi>a</mi><mi>t</mi><mi>i</mi><mi>o</mi><mi>n</mi><mtext> </mtext><mi>I</mi><mi>n</mi><mi>h</mi><mi>i</mi><mi>b</mi><mi>i</mi><mi>t</mi><mi>i</mi><mi>o</mi><mi>n</mi><mo>=</mo><mfrac><mrow><mrow><mo>(</mo><mrow><mi>M</mi><mi>e</mi><mi>a</mi><mi>n</mi><mtext> </mtext><mi>O</mi><msub><mi>D</mi><mrow><mi>P</mi><mi>o</mi><mi>s</mi><mi>i</mi><mi>t</mi><mi>i</mi><mi>v</mi><mi>e</mi><mtext> </mtext><mi>c</mi><mi>o</mi><mi>n</mi><mi>t</mi><mi>r</mi><mi>o</mi><mi>l</mi></mrow></msub><mo>−</mo><mi>M</mi><mi>e</mi><mi>a</mi><mi>n</mi><mtext> </mtext><mi>O</mi><msub><mi>D</mi><mrow><mi>P</mi><mi>o</mi><mi>s</mi><mi>i</mi><mi>t</mi><mi>i</mi><mi>v</mi><mi>e</mi><mtext> </mtext><mi>c</mi><mi>o</mi><mi>n</mi><mi>t</mi><mi>r</mi><mi>o</mi><mi>l</mi><mo>+</mo><mi>N</mi><mi>a</mi><mi>n</mi><mi>o</mi><mi>p</mi><mi>a</mi><mi>r</mi><mi>t</mi><mi>i</mi><mi>c</mi><mi>l</mi><mi>e</mi><mi>s</mi></mrow></msub></mrow><mo>)</mo></mrow></mrow><mrow><mi>M</mi><mi>e</mi><mi>a</mi><mi>n</mi><mtext> </mtext><mi>O</mi><msub><mi>D</mi><mrow><mi>P</mi><mi>o</mi><mi>s</mi><mi>i</mi><mi>t</mi><mi>i</mi><mi>v</mi><mi>e</mi><mtext> </mtext><mi>c</mi><mi>o</mi><mi>n</mi><mi>t</mi><mi>r</mi><mi>o</mi><mi>l</mi></mrow></msub><mo>−</mo><mi>M</mi><mi>e</mi><mi>a</mi><mi>n</mi><mtext> </mtext><mi>O</mi><msub><mi>D</mi><mrow><mi>U</mi><mi>n</mi><mi>t</mi><mi>r</mi><mi>e</mi><mi>a</mi><mi>t</mi><mi>e</mi><mi>d</mi><mtext> </mtext><mi>c</mi><mi>e</mi><mi>l</mi><mi>l</mi><mi>s</mi></mrow></msub></mrow></mfrac><mo>∗</mo><mn>100</mn><mi>%</mi></mrow></math></div><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow last bk_equ_label "><div><span class="nowrap"></span></div></div></div>
|
|
<blockquote><p><i>Note:</i>
|
|
<dl id="ncipr43.l9" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd id="ncipr43.lt62"><p class="no_top_margin"><i>The calculations above are done with the assumption that an increase in the number of viable cells detected by this assay is due to proliferation and not due to the increase in the longevity of the individual cells in culture</i>.</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd id="ncipr43.lt63"><p class="no_top_margin"><i>If the percent inhibition is negative, this indicates that the test compound increased proliferation instead of decreasing it</i>.</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd id="ncipr43.lt64"><p class="no_top_margin"><i>Percent proliferation values above negative control observed in the no cell control samples suggest that nanoparticles interfere with the assay in a false positive way</i>.</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd id="ncipr43.lt65"><p class="no_top_margin"><i>When comparing leukocyte proliferation in nanoparticle+PC sample, use proliferation in PC2 as a benchmark</i>.</p></dd></dl></dl></p></blockquote></p></dd></dl></dl></div><div id="ncipr43.s9"><h2 id="_ncipr43_s9_">9. Acceptance Criteria</h2><dl id="ncipr43.l10" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>9.1.</dt><dd id="ncipr43.lt66"><p class="no_top_margin">%CV for each control and test sample should be less than 30%.</p></dd></dl><dl class="bkr_refwrap"><dt>9.2.</dt><dd id="ncipr43.lt67"><p class="no_top_margin">When positive control (PC2) or negative control fails to meet acceptance criterion described in <a href="#ncipr43.lt66">9.1</a>, the assay should be repeated.</p></dd></dl><dl class="bkr_refwrap"><dt>9.3.</dt><dd id="ncipr43.lt68"><p class="no_top_margin">Within the acceptable assay, if two of three replicates of unknown sample fail to meet acceptance criterion described in <a href="#ncipr43.lt66">9.1</a>, this unknown sample should be reanalyzed.</p></dd></dl><dl class="bkr_refwrap"><dt>9.4.</dt><dd id="ncipr43.lt69"><p class="no_top_margin">If two duplicates of the same study sample demonstrated results different by more than 30%, this sample should be reanalyzed.</p></dd></dl><dl class="bkr_refwrap"><dt>9.5.</dt><dd id="ncipr43.lt70"><p class="no_top_margin">If significant variability is observed in results obtained using leukocytes from three initial donors, the experiment needs to be repeated with additional donor cells.</p></dd></dl></dl></div><div id="ncipr43.rl.r1"><h2 id="_ncipr43_rl_r1_">10. References</h2><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="ncipr43.ref1">Current Protocols in Immunology. Edited by: John E.
|
|
Coligan (NIAID, NIH); Barbara
|
|
Bierer (Brigham & Women’s Hospital); David H.
|
|
Margulies (NIAID, NIH); Ethan M.
|
|
Shevach (NIAID, NIH); Warren
|
|
Strober (NIAID, NIH); Richard
|
|
Coico (Weill Medical College of Cornell University); John Wiley & Sons, Inc., 2005.</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="ncipr43.ref2">Standard practice for evaluation of immune responses in biocompatibility testing using ELISA tests, lymphocytes proliferation, and cell migration. ASTM F1906-98.</div></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><div class="bk_ref" id="ncipr43.ref3">Dobrovolskaia
|
|
MA, McNeil
|
|
SE. Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. J Control Release. 2013;172(2):456–66.
|
|
[<a href="/pmc/articles/PMC5831149/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5831149</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23742883" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23742883</span></a>]</div></dd></dl></dl></div><div id="ncipr43.s10"><h2 id="_ncipr43_s10_">11. Abbreviations</h2><dl><dt id="ncipr43.abb_DL1_DI1">CV</dt><dd><p>coefficient of variation</p></dd><dt id="ncipr43.abb_DL1_DI2">DMSO</dt><dd><p>dimethyl sulfoxide</p></dd><dt id="ncipr43.abb_DL1_DI3">FBS</dt><dd><p>fetal bovine serum</p></dd><dt id="ncipr43.abb_DL1_DI4">HBSS</dt><dd><p>Hank’s balanced salt solution</p></dd><dt id="ncipr43.abb_DL1_DI5">MTT</dt><dd><p>3-(4, 5-dimethyl-2-thiazolyl)-2.5-diphenyl-2H-tetrazolium bromide</p></dd><dt id="ncipr43.abb_DL1_DI6">OD</dt><dd><p>optical density</p></dd><dt id="ncipr43.abb_DL1_DI7">PBS</dt><dd><p>phosphate buffered saline</p></dd><dt id="ncipr43.abb_DL1_DI8">PHA-M</dt><dd><p>phytohemaglutinin</p></dd><dt id="ncipr43.abb_DL1_DI9">RPMI</dt><dd><p>Roswell Park Memorial Institute</p></dd><dt id="ncipr43.abb_DL1_DI10">SD</dt><dd><p>standard deviation</p></dd><dt id="ncipr43.abb_DL1_DI11">TS</dt><dd><p>test sample</p></dd><dt id="ncipr43.abb_DL1_DI12">VC</dt><dd><p>vehicle control</p></dd></dl></div><div id="ncipr43.app1"><h2 id="_ncipr43_app1_">12. Appendix</h2><div id="ncipr43.app1.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Example%20Plate%20Map.&p=BOOKS&id=612354_ncipr43app1f1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK612354/bin/ncipr43app1f1.jpg" alt="Example Plate Map." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="title">Example Plate Map</span></h3><div class="caption"><p>Wells 1-4 in Rows G & H are the cell-free test samples; they do not receive cells.</p><p>NC: Negative Control; PC: Positive Control; TS: Test Sample; VC: Vehicle Control</p><p><b>Note</b>: PC1 on this template refers to the working solution of the positive control with a concentration 20 μg/mL. The final concentration of PHA-M in this sample is 5 μg/mL. The data from nanoparticles+PC1 wells should be compared to the data in PC2 wells.</p></div></div></div><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_top_margin"><p>This protocol assumes an intermediate level of scientific competency with regard to techniques, instrumentation, and safety procedures. Rudimentary assay details have been omitted for the sake of brevity.</p></p></div></dd></dl><dl class="bkr_refwrap"><dt>*</dt><dd><div id="ncipr43.fn1"><p class="no_top_margin">address correspondence to: <a href="mailto:dev@null" data-email="vog.hin.liam@aniram" class="oemail">vog.hin.liam@aniram</a></p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_top_margin"><div>
|
|
<span class="mixed-citation" id="ncipr43.suggestedcitation">Potter TM, Cedrone E, Skoczen SL, Neun BW, Dobrovolskaia MA, NCL Method ITA-6.1: Leukocyte Proliferation Assay (Immunostimulation and Immunosuppression). <a href="https://ncl.cancer.gov/resources/assay-cascade-protocols" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">https://ncl.cancer.gov/resources/assay-cascade-protocols</a> DOI: <a href="http://dx.crossref.org/10.17917/PJNB-JJ95" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">10.17917/PJNB-JJ95</a></span>
|
|
</div></p></div></dd></dl></dl></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK612354_pubdet_">Publication Details</h2><h3>Author Information and Affiliations</h3><p class="contrib-group"><h4>Authors</h4><span itemprop="author">Timothy M. Potter</span>, <span itemprop="author">Edward Cedrone</span>, <span itemprop="author">Sarah L. Skoczen</span>, <span itemprop="author">Barry W. Neun</span>, and <span itemprop="author">Marina A. Dobrovolskaia</span><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup><sup>1</sup>.</p><h4>Contact</h4><div class="affiliation"><sup>1</sup> <span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.liam@aniram" class="oemail">vog.hin.liam@aniram</a></div><div class="affiliation"><sup>1</sup> Nanotechnology Characterization Lab, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD 21702</div><div><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup>Corresponding author.</div><h3>Publication History</h3><p class="small">Published: <span itemprop="datePublished">July 2024</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="https://www.cancer.gov/nano/research/ncl" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Cancer Institute (US)</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>Potter TM, Cedrone E, Skoczen SL, et al. Leukocyte Proliferation Assay (Immunostimulation and Immunosuppression): Version 4.2. 2024 Jul. In: National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols [Internet]. Bethesda (MD): National Cancer Institute (US); 2005 May 1-. NCL Method ITA-6.1.<span class="bk_cite_avail"></span> doi: 10.17917/PJNB-JJ95</p></div><div class="small-screen-prev"><a href="/books/n/nciprotocols/ncipr57/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/nciprotocols/ncipr41/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="boxed-text" id="figobncipr43box1"><div id="ncipr43.box1" class="box boxed-text-box whole_rhythm hide-overflow"><h3><span class="label">Box 1</span><span class="title">Example Calculation to Determine Nanoparticle Concentration for In Vitro Tests</span></h3><p>In this example, we assume a mouse dose of 123 mg/kg. Therefore, the scaled equivalent human dose would be:
|
|
<div class="pmc_disp_formula whole_rhythm clearfix" id="ncipr43.deq1"><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow twelve_col"><math id="ncipr43.eq1" display="block"><mrow><mi>H</mi><mi>u</mi><mi>m</mi><mi>a</mi><mi>n</mi><mtext> </mtext><mi>d</mi><mi>o</mi><mi>s</mi><mi>e</mi><mo>=</mo><mfrac><mrow><mi>m</mi><mi>o</mi><mi>u</mi><mi>s</mi><mi>e</mi><mtext> </mtext><mi>d</mi><mi>o</mi><mi>s</mi><mi>e</mi></mrow><mrow><mn>12.3</mn></mrow></mfrac><mo>=</mo><mfrac><mrow><mn>123</mn><mtext> </mtext><mi>m</mi><mi>g</mi><mo>/</mo><mi>k</mi><mi>g</mi></mrow><mrow><mn>12.3</mn></mrow></mfrac><mo>=</mo><mn>10</mn><mtext> </mtext><mi>m</mi><mi>g</mi><mo>/</mo><mi>k</mi><mi>g</mi></mrow></math></div><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow last bk_equ_label "><div><span class="nowrap"></span></div></div></div></p><p>Blood volume constitutes approximately 8% of the body weight. Therefore, an average human of 70 kg body weight has approximately 5.6 L of blood. Assuming all the nanoparticle injected goes into the systemic circulation, this provides a rough approximation of the potential maximum nanoparticle concentration in blood, which is used as the in vitro test concentration.</p><div class="pmc_disp_formula whole_rhythm clearfix" id="ncipr43.deq2"><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow twelve_col">
|
|
<math id="ncipr43.eq2" display="block"><mrow><mi>i</mi><mi>n</mi><mtext> </mtext><mi>v</mi><mi>i</mi><mi>t</mi><mi>r</mi><mi>o</mi><mtext> </mtext><mi>c</mi><mi>o</mi><mi>n</mi><mi>c</mi><mi>e</mi><mi>n</mi><mi>t</mi><mi>r</mi><mi>a</mi><mi>t</mi><mi>i</mi><mi>o</mi><msub><mi>n</mi><mrow><mi>h</mi><mi>u</mi><mi>m</mi><mi>a</mi><mi>n</mi><mtext> </mtext><mi>m</mi><mi>a</mi><mi>t</mi><mi>r</mi><mi>i</mi><mi>x</mi></mrow></msub><mo>=</mo><mfrac><mrow><mi>h</mi><mi>u</mi><mi>m</mi><mi>a</mi><mi>n</mi><mtext> </mtext><mi>d</mi><mi>o</mi><mi>s</mi><mi>e</mi></mrow><mrow><mi>h</mi><mi>u</mi><mi>m</mi><mi>a</mi><mi>n</mi><mtext> </mtext><mi>b</mi><mi>l</mi><mi>o</mi><mi>o</mi><mi>d</mi><mtext> </mtext><mi>v</mi><mi>o</mi><mi>l</mi><mi>u</mi><mi>m</mi><mi>e</mi></mrow></mfrac><mo>=</mo><mfrac><mrow><mn>70</mn><mtext> </mtext><mi>k</mi><mi>g</mi><mo>∗</mo><mn>10</mn><mtext> </mtext><mi>m</mi><mi>g</mi><mo>/</mo><mi>k</mi><mi>g</mi></mrow><mrow><mn>5.6</mn><mtext> </mtext><mi>L</mi></mrow></mfrac><mo>=</mo><mn>0.125</mn><mtext> </mtext><mi>m</mi><mi>g</mi><mo>/</mo><mi>m</mi><mi>L</mi></mrow></math>
|
|
</div><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow last bk_equ_label "><div><span class="nowrap"></span></div></div></div></div></article><article data-type="fig" id="figobncipr43app1fig1"><div id="ncipr43.app1.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Example%20Plate%20Map.&p=BOOKS&id=612354_ncipr43app1f1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK612354/bin/ncipr43app1f1.jpg" alt="Example Plate Map." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="title">Example Plate Map</span></h3><div class="caption"><p>Wells 1-4 in Rows G & H are the cell-free test samples; they do not receive cells.</p><p>NC: Negative Control; PC: Positive Control; TS: Test Sample; VC: Vehicle Control</p><p><b>Note</b>: PC1 on this template refers to the working solution of the positive control with a concentration 20 μg/mL. The final concentration of PHA-M in this sample is 5 μg/mL. The data from nanoparticles+PC1 wells should be compared to the data in PC2 wells.</p></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script><script type="text/javascript" src="/core/mathjax/2.7.9/MathJax.js?config=TeX-AMS-MML_SVG"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal105 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|